CUV

Clinuvel PharmaceuticalsASX:CUV Stock Report

Market Cap

AU$2.1b

7D

3.8%

1Y

82.3%

Updated

18 Sep, 2021

Data

Company Financials +
CUV fundamental analysis
Snowflake Score
Valuation1/6
Future Growth6/6
Past Performance5/6
Financial Health6/6
Dividends0/6

CUV Overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Clinuvel Pharmaceuticals
Historical stock prices
Current Share PriceAU$41.71
52 Week HighAU$19.63
52 Week LowAU$42.20
Beta0.46
1 Month Change45.13%
3 Month Change43.04%
1 Year Change82.30%
3 Year Change120.22%
5 Year Change583.77%
Change since IPO4,071.00%

Recent News & Updates

Jul 23
Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Shareholder Returns

CUVAU BiotechsAU Market
7D3.8%2.5%-0.02%
1Y82.3%10.4%27.0%

Return vs Industry: CUV exceeded the Australian Biotechs industry which returned 10.4% over the past year.

Return vs Market: CUV exceeded the Australian Market which returned 27% over the past year.

Price Volatility

Is CUV's price volatile compared to industry and market?
CUV volatility
CUV Beta0.46
Industry Beta1.67
Market Beta1

Stable Share Price: CUV is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CUV's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aPhilippe Wolgenhttps://www.clinuvel.com

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.

Clinuvel Pharmaceuticals Fundamentals Summary

How do Clinuvel Pharmaceuticals's earnings and revenue compare to its market cap?
CUV fundamental statistics
Market CapAU$2.06b
Earnings (TTM)AU$24.73m
Revenue (TTM)AU$47.98m

83.3x

P/E Ratio

43.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CUV income statement (TTM)
RevenueAU$47.98m
Cost of RevenueAU$6.78m
Gross ProfitAU$41.20m
ExpensesAU$16.47m
EarningsAU$24.73m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.50
Gross Margin85.88%
Net Profit Margin51.54%
Debt/Equity Ratio0%

How did CUV perform over the long term?

See historical performance and comparison

Dividends

0.06%

Current Dividend Yield

5%

Payout Ratio

Valuation

Is Clinuvel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

1.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CUV (A$41.71) is trading below our estimate of fair value (A$42.52)

Significantly Below Fair Value: CUV is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: CUV is poor value based on its PE Ratio (83.3x) compared to the Global Biotechs industry average (35.3x).

PE vs Market: CUV is poor value based on its PE Ratio (83.3x) compared to the Australian market (18.7x).


Price to Earnings Growth Ratio

PEG Ratio: CUV is poor value based on its PEG Ratio (2.6x)


Price to Book Ratio

PB vs Industry: CUV is overvalued based on its PB Ratio (20.9x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Clinuvel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

32.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CUV's forecast earnings growth (32% per year) is above the savings rate (1.9%).

Earnings vs Market: CUV's earnings (32% per year) are forecast to grow faster than the Australian market (11.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CUV's revenue (31.6% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: CUV's revenue (31.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CUV's Return on Equity is forecast to be high in 3 years time (29.9%)


Past Performance

How has Clinuvel Pharmaceuticals performed over the past 5 years?

36.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CUV has a high level of non-cash earnings.

Growing Profit Margin: CUV's current net profit margins (51.5%) are higher than last year (46.2%).


Past Earnings Growth Analysis

Earnings Trend: CUV has become profitable over the past 5 years, growing earnings by 36.5% per year.

Accelerating Growth: CUV's earnings growth over the past year (64.3%) exceeds its 5-year average (36.5% per year).

Earnings vs Industry: CUV earnings growth over the past year (64.3%) exceeded the Biotechs industry 41.5%.


Return on Equity

High ROE: CUV's Return on Equity (25%) is considered high.


Financial Health

How is Clinuvel Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CUV's short term assets (A$102.8M) exceed its short term liabilities (A$8.7M).

Long Term Liabilities: CUV's short term assets (A$102.8M) exceed its long term liabilities (A$1.1M).


Debt to Equity History and Analysis

Debt Level: CUV is debt free.

Reducing Debt: CUV has not had any debt for past 5 years.

Debt Coverage: CUV has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CUV has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Clinuvel Pharmaceuticals's current dividend yield, its reliability and sustainability?

0.06%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CUV's dividend (0.06%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.3%).

High Dividend: CUV's dividend (0.06%) is low compared to the top 25% of dividend payers in the Australian market (5.41%).


Stability and Growth of Payments

Stable Dividend: CUV is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.

Growing Dividend: CUV is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: CUV is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CUV's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

15.7yrs

Average management tenure


CEO

Philippe Wolgen (58 yo)

15.83yrs

Tenure

AU$2,667,538

Compensation

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....


CEO Compensation Analysis

Compensation vs Market: Philippe's total compensation ($USD1.94M) is above average for companies of similar size in the Australian market ($USD1.28M).

Compensation vs Earnings: Philippe's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CUV's management team is seasoned and experienced (15.7 years average tenure).


Board Members

Experienced Board: CUV's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CUV insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Clinuvel Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Clinuvel Pharmaceuticals Limited
  • Ticker: CUV
  • Exchange: ASX
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$2.061b
  • Shares outstanding: 49.41m
  • Website: https://www.clinuvel.com

Location

  • Clinuvel Pharmaceuticals Limited
  • 535 Bourke Street
  • Level 11
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 08:03
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.